Press releases
Stay up to date with our activities by browsing our press releases and company presentations below.
Subscribe
Get press releases directly to your email.
Stay up to date with our activities by browsing our press releases and company presentations below.
Get press releases directly to your email.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
The members of Gesynta Pharma's management team and board of directors have extensive experience from drug development and commercialization.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase II for endometriosis, while GS-073 is ready to enter clinical phase I for chronic inflammatory pain.
